CBD - BIOAVAILABILITY STUDY - LIPOSOMAL V. STANDARD OIL
CBD is one of over 60 compounds found in cannabis that belong to a class of molecules called cannabinoids.
Your brain creates its own set of cannabinoids — similar to those found in cannabis — via the endocannabinoid system.
The endocannabinoid system is responsible for many important bodily functions such as appetite, sleep, emotion and movement.
CBD oil does not only contain cannabidiol as its sole ingredient. There are a number of other phyto-cannabinoids such as CBG, CBN, CBC along with a number of different amino acids, carbohydrates, fatty acids, minerals and vitamins all of which are an important constituent of CBD oil.
Lipolife® CBD products use an ethically sourced, organic, European hemp oil.
Formulated using CO2 extraction, Lipolife® Liposomal CBD uses a full spectrum hemp extract from Cannabis Sativa, providing a mix of different cannabinoids, including 60% CBD and plant derived terpenes.
WHY LIPOSOMAL CBD?
Oral bioavailability of CBD is relatively poor, with scientific literature reporting absorption between 6% for regular oral CBD and around 15% for oil based, mucosal CBD sprays.
This evidence of poor absorption via oral administration creates an opportunity to utilise our proprietary liposomal encapsulation technology and improve upon the bioavailability of oral CBD.
To prove the efficacy of our Lipolife® CBD we commissioned a bioavailability study.
The Oral Bioavailability of Liposome Encapsulated CBD Formulations Compared to Commercial CBD Oil.
CBD is a naturally occurring cannabinoid possessing therapeutic properties including anti-inflammatory, anxiolytic, analgesic and neuroprotection (Noreen et al., 2018).
The objective of this study was to investigate the pharmacokinetic properties of CBD when administered in different forms to determine relative bioavailability and prove that liposome encapsulated CBD formulations can supersede the bioavailability of standard commercial oil preparations.
This study involved nine participants and three formulations of CBD at 250mg including a Curcumin and CBD combination.
All formulations reached peak absorption between approximately 120-180 minutes.
Figure 1 represents the peak absorption of each CBD product tested. It is clear from this data that the Liposomal product is far better absorbed than the regular oil with the results showing a 4-fold increase.
The combination of Liposomal CBD and Liposomal Curcumin was found to be slightly better absorbed than regular Liposomal CBD.
Figure 2 represents the total amount of time the CBD is measurable in the blood, combined with the total concentration in the blood over that period of time. The longer the ingredient is able to remain active in the blood the greater its efficacy.
The graph clearly shows the Liposomal CBD remained active in the blood for a much greater period of time when compared with the standard CBD oil, and even longer for the CBD combined with Liposomal Curcumin.
In this study it has been proven that Liposomal formulations are a superior method of oral delivery compared to commercial CBD in an oil-based solution.
The addition of Liposomal Curcumin further enhances the bioavailability and efficacy of Liposomal CBD.
Study carried out by the University of Nottingham.